We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medpace (MEDP) Rises As Market Takes a Dip: Key Facts
Read MoreHide Full Article
Medpace (MEDP - Free Report) closed the most recent trading day at $447.09, moving +2.06% from the previous trading session. The stock outpaced the S&P 500's daily loss of 0.54%. Elsewhere, the Dow saw an upswing of 0.03%, while the tech-heavy Nasdaq depreciated by 1.18%.
The provider of outsourced clinical development services's shares have seen a decrease of 26.73% over the last month, not keeping up with the Medical sector's loss of 0.62% and the S&P 500's gain of 0.58%.
The upcoming earnings release of Medpace will be of great interest to investors. The company's earnings per share (EPS) are projected to be $3.74, reflecting a 1.91% increase from the same quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $694.24 million, up 24.29% from the year-ago period.
For the full year, the Zacks Consensus Estimates project earnings of $17.07 per share and a revenue of $2.81 billion, demonstrating changes of +11.71% and +11%, respectively, from the preceding year.
Any recent changes to analyst estimates for Medpace should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. The Zacks Consensus EPS estimate has moved 2.66% higher within the past month. Medpace is holding a Zacks Rank of #3 (Hold) right now.
Investors should also note Medpace's current valuation metrics, including its Forward P/E ratio of 25.67. This signifies a premium in comparison to the average Forward P/E of 16.26 for its industry.
It's also important to note that MEDP currently trades at a PEG ratio of 2.1. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The average PEG ratio for the Medical Services industry stood at 1.69 at the close of the market yesterday.
The Medical Services industry is part of the Medical sector. With its current Zacks Industry Rank of 150, this industry ranks in the bottom 39% of all industries, numbering over 250.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Medpace (MEDP) Rises As Market Takes a Dip: Key Facts
Medpace (MEDP - Free Report) closed the most recent trading day at $447.09, moving +2.06% from the previous trading session. The stock outpaced the S&P 500's daily loss of 0.54%. Elsewhere, the Dow saw an upswing of 0.03%, while the tech-heavy Nasdaq depreciated by 1.18%.
The provider of outsourced clinical development services's shares have seen a decrease of 26.73% over the last month, not keeping up with the Medical sector's loss of 0.62% and the S&P 500's gain of 0.58%.
The upcoming earnings release of Medpace will be of great interest to investors. The company's earnings per share (EPS) are projected to be $3.74, reflecting a 1.91% increase from the same quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $694.24 million, up 24.29% from the year-ago period.
For the full year, the Zacks Consensus Estimates project earnings of $17.07 per share and a revenue of $2.81 billion, demonstrating changes of +11.71% and +11%, respectively, from the preceding year.
Any recent changes to analyst estimates for Medpace should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. The Zacks Consensus EPS estimate has moved 2.66% higher within the past month. Medpace is holding a Zacks Rank of #3 (Hold) right now.
Investors should also note Medpace's current valuation metrics, including its Forward P/E ratio of 25.67. This signifies a premium in comparison to the average Forward P/E of 16.26 for its industry.
It's also important to note that MEDP currently trades at a PEG ratio of 2.1. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The average PEG ratio for the Medical Services industry stood at 1.69 at the close of the market yesterday.
The Medical Services industry is part of the Medical sector. With its current Zacks Industry Rank of 150, this industry ranks in the bottom 39% of all industries, numbering over 250.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.